最近更新 | Last Updated: 2022-05-25
| Product Name / Description
药品名称 / 描述 |
Marketing Authorization Holder
上市许可持有人 |
Dosage and Administration
剂量和给药 |
Patent No.
相关专利号 |
Claim No.
权利要求项编号 |
Patent Type
专利类型 |
Expiration
保护期届满日2 |
|
| Freeze-dried Live Attenuated Hepatitis A Vaccine
冻干甲型肝炎减毒活疫苗 Live attenuated hepatitis A vaccine 甲型肝炎减毒活疫苗 |
Changsheng Biotechnology
长春生物 |
0.5 mL
Injection | 注射剂 |
ZL200810051441.9 | 1 | Medical use
医药用途 |
2028-11-17 | |
| Daratumumab
达雷妥尤单抗 CD38 antibody CD38抗体 |
Genmab
根马布 |
1800 mg
Injection | 注射剂 |
ZL200680017915.7
|
1-4, 6, 8-10, 13, 29, 30, 34-36, 40, 41 | Sequence of active biological ingredients;
Medical use 生物制品活性成分的序列结构; 医药用途 |
2026-03-22 | |
| ZL201710164800.0 | 19, 20, 22, 25-27, 29, 30 | Medical use
医药用途 |
2026-03-22 | ||||
| Dupilumab
度普利尤单抗 IL-4 Receptor antibody IL-4受体抗体 |
Regeneron Pharmaceuticals
再生元制药 |
200 mg
Injection | 注射剂 |
ZL200980143007.6 | 1-5, 13, 16 | Sequence of active biological ingredients;
Medical use 生物制品活性成分的序列结构; 医药用途 |
2029-10-27 | |
| ZL201410018529.6 | 1-8, 16 | Sequence of active biological ingredients;
Medical use 生物制品活性成分的序列结构; 医药用途 |
2029-10-27 | ||||
| Semaglutide
司美格鲁肽 (OZEMPIC®, 诺和泰®) GLP-1 GLP-1化合物 |
Novo Nordisk
诺和诺德 |
1.34 mg/mL (3 mL), 1.34 mg/mL (1.5 mL)
Prefilled injection pen | 预填充注射笔 |
ZL200680006674.6 | 1, 3, 4 | Sequence of active biological ingredients;
Medical use 生物制品活性成分的序列结构; 医药用途 |
2026-03-20 | |
| Velaglucerase alfa
维拉苷酶α (VPRIV®, 维葡瑞 ®) Velaglucerase alfa 维拉苷酶α |
Takeda Pharmaceutical
武田药品 |
400 U
Injection | 注射剂 |
ZL201510580649.X | 27 | Medical use
医药用途 |
2030-07-27 | |
| Ainocoagulant alfa
艾诺凝血素α (ALPROLIX®，赛玖凝®) Coagulation factor IX-Fc fusion protein 凝血因子IX-Fc融合蛋白 |
Bioverativ Therapeutics | 250, 500, 1000, 2000 IU
Injection | 注射剂 |
ZL200480019188.9 | 1, 4, 6-8, 12, 14, 30, 70-71, 81, 83, 85, 88, 90-95, 97-98, 105, 107, 112, 115, 117, 119, 122-124 | Sequence of active biological ingredients;
Medical use 生物制品活性成分的序列结构; 医药用途 |
2024-05-06 | |
| ZL201110082150.8 | 1,4-7, 10, 15, 17, 19-20, 24, 27, 30-31, 36, 38, 41, 44-46, 49, 51, 53, 59 | Sequence of active biological ingredients;
Medical use 生物制品活性成分的序列结构; 医药用途 |
2024-05-06 | ||||
| ZL201410443460.1 | 1, 16-18, 21-26, 32, 41-42, 44, 46 | Sequence of active biological ingredients;
Medical use 生物制品活性成分的序列结构; 医药用途 |
2024-05-06 | ||||
| Guselkumab
古塞奇尤单抗 IL-23 antibody IL-23抗体 |
Janssen Biotech詹森生物 | 100 mg
Injection | 注射剂
|
ZL200680053546.7 | 2, 4-8, 21-25 | Sequence of active biological ingredients
生物制品活性成分的序列结构 |
2026-12-27 | |
| ZL201210297501.1 | 1-5 | Sequence of active biological ingredients
生物制品活性成分的序列结构 |
2026-12-27 | ||||
| Golimumab
戈利木单抗 TNF antibody TNF抗体 |
Janssen Biotech詹森生物 | 50 mg
Injection | 注射剂 |
ZL01816960.0 | 1-3, 10-12 | Sequence of active biological ingredients
生物制品活性成分的序列结构 |
2021-08-06 | |
| ZL201010156291.5 | 1-8 | Medical use
医药用途 |
2021-08-06 | ||||
| Evolocumab
依洛尤单抗 (REPATHA®, 瑞百安®) PCSK9 antibody PCSK9抗体 |
Amgen Inc.
安进公司 |
140 mg
Injection | 注射剂
|
ZL201380035382.5 | 17-20 | Medical use
医药用途 |
2033-05-02 | |
| ZL200880113475.4 | 1-7, 9-14, 16-17, 25-29 | Sequence of active biological ingredients;
Medical use 生物制品活性成分的序列结构; 医药用途 |
2028-08-21 | ||||
| ZL201280034417.9 | 2-23, 27, 33-35, 37, 39, 40, 42, 43, 47-52, 54-58, 60 | Medical use
医药用途 |
2023-05-09 | ||||
| Lanadelumab
拉那利尤单抗 (AKHZYRO®, 达泽优®) Plasma kallikrein binding protein 血浆前激肽释放酶结合蛋白 |
Takeda Pharmaceutical
武田药品 |
300 mg
Injection | 注射剂 |
ZL201280011286.2 | 1-3, 5, 6, 9 | Sequence of active biological ingredients;
Medical use 生物制品活性成分的序列结构; 医药用途 |
2032-01-05 | |
| ZL201610164388.8 | 1-3 | Sequence of active biological ingredients
生物制品活性成分的序列结构 |
2320-01-05 | ||||
| Insulin Glargine
甘精胰岛素 (LANTUS®, 来得时 ®) Insulin Glargine Injection 甘精胰岛素制剂 |
Sanofi
赛诺菲 |
450 U
Injection | 注射剂
|
ZL201480020095.1 | 1-15, 17-18, 20-32 | Medical use
医药用途 |
2034-04-01 | |
| Disitamab
维迪西妥单抗 （AIDIXI®, 爱地希®） Anti-HER2 ADC 抗HER2抗体及其缀合物 |
RemeGen
荣昌生物 |
60 mg
Injection | 注射剂
|
ZL201480006648.8 | 1, 14 | Sequence of active biological ingredients
生物制品活性成分的序列结构 |
2034-11-18 | |
| Telitacicept
泰它西普 (RC18, 泰爱®) TACI-Fc fusion protein TACI-Fc融合蛋白 |
RemeGen
荣昌生物 |
80 mg
Injection | 注射剂 |
ZL200710111162.2 | 1, 9 | Sequence of active biological ingredients
生物制品活性成分的序列结构 |
2027-06-15 | |
| Artemisia annua pollen allergen sublingual drops
黄花蒿花粉变应原舌下滴剂 (畅皓®) Drug group containing Artemisia pollen allergens 含有蒿属花粉变应原的药物组 |
Wolwo Biopharma
我武生物 |
50, 256, 1280, 6400,
32000 BU Drop | 滴剂 |
200910147470.X | 39-41 | Medical use
医药用途 |
2029-06-08 | |
| 13-valent pneumococcal polysaccharide conjugate vaccine
13价肺炎球菌多糖结合疫苗 13-valent pneumococcal polysaccharide conjugate composition 13价肺炎球菌多糖-蛋白结合物组合物 |
Walvax Biotechnology
沃森生物 |
0.5 mL
Injection | 注射剂 |
ZL201810053602.1 | 1-3 | Medical use
医药用途 |
2038-01-19 | |
| Tislelizumab
替雷利珠单抗 (百泽安®) PD1 antibody PD1抗体
|
BeiGene
百济神州 |
100mg
Injection | 注射剂 |
ZL201380079581.6 | 3-7, 8-14 | Sequence of active biological ingredients;
Medical use 生物制品活性成分的序列结构; 医药用途 |
2033-09-12 | |
| ZL201710207300 .0 | 1, 2 | Sequence of active biological ingredients;
Medical use 生物制品活性成分的序列结构; 医药用途 |
2033-09-12 | ||||
| ZL201710208535.1 | 1 | Sequence of active biological ingredients
生物制品活性成分的序列结构 |
2033-09-12 | ||||
| ZL201810552595 .X | 1 | Sequence of active biological ingredients
生物制品活性成分的序列结构 |
2033-09-12 | ||||
| Camrelizumab, 卡瑞利珠单抗
（AiRuiKa™, 艾瑞卡®） PD-1 antibody PD-1抗体 |
Jiangsu Hengrui Medicine
恒瑞医药 |
200 mg
Injection | 注射剂 |
ZL201480011008.6 | 1, 6-11, 21-26 | Sequence of active biological ingredients;
Medical use 生物制品活性成分的序列结构; 医药用途
|
2034-11-14 | |
| Sintilimab
信迪利单抗注射液 (TYVYT®, 达伯舒®) PD-1 antibody PD-1抗体 |
Innovent Biologics
信达生物 |
100 mg
Injection | 注射剂 |
ZL201680040482.0 | 1, 3, 5, 7, 9, 11, 16, 18, 23, 24, 27, 29, 30 | Sequence of active biological ingredients;
Medical use 生物制品活性成分的序列结构; 医药用途 |
2036-08-09 | |
| 培集成干扰素α-2注射液
（派益生®) Peginterferon alfacon-2 培集成干扰素α-2 |
Beijing Kawin Technology
凯因科技 |
0.15 mg
Injection | 注射剂 |
ZL201410146151.8 | 1 | Sequence of active biological ingredients
生物制品活性成分的序列结构 |
2030-10-25 | |
| Mecapegfilgrastim
硫培非格司亭注射液 (艾多®) Pegylated recombinant G-CSF 聚乙二醇化重组人粒细胞刺激因子
|
Jiangsu Hengrui Medicine
恒瑞医药 |
6 mg
Injection | 注射剂 |
ZL200610142737.2 | 1-4, 6, 10, 12 | Sequence of active biological ingredients;
Medical use 生物制品活性成分的序列结构; 医药用途 |
2026-10-30 | |
| Conbercept
康柏西普眼用注射液 (LUMITIN®, 朗沐®) VEGF receptor fusion with Fc VEGF 受体与Fc融合蛋白 |
Chengdu Kanghong Pharmaceutical Group
康弘药业 |
10 mg/mL
Injection | 注射剂 |
ZL200510073595.4 | 1, 5 | Sequence of active biological ingredients;
Medical use 生物制品活性成分的序列结构; 医药用途 |
2025-06-06 | |
| 人干扰素α1b注射液
(运德素®) Recombinant human IFN-α1b 重组人干扰素α1b |
Tri-Prime Gene
三元基因 |
6, 10, 20, 30, 40, 50μg,
Injection | 注射剂 |
ZL200410069390.4 | 1-3 | Medical use
医药用途 |
2024-07-22 | |
| 德谷门冬双胰岛素注射液
(RYZODEG®, 诺和佳®) Insulin degludec and insulin aspart 德谷门冬双胰岛素 |
Novo Nordisk
诺和诺德 |
300 U
Injection | 注射剂 |
ZL200480021733.8 | 1-4, 8-10 | Sequence of active biological ingredients;
Medical use 生物制品活性成分的序列结构; 医药用途 |
2024-07-22 | |
| Insulin degludec,
德谷胰岛素注射液 (TRESIBA®, 诺和达®) Long-acting insulin 长效基础胰岛素类似物 |
Novo Nordisk诺和诺德 | 300 U
Injection | 注射剂 |
ZL200480021733.8 | 1-4;
8-10 |
Sequence of active biological ingredients;
Medical use 生物制品活性成分的序列结构; 医药用途 |
2024-07-22 | |
| Satralizumab
萨特利珠单抗注射液 (ENSPRYNG®, 安适平®) IL-6 receptor antibody IL-6受体单抗 |
Roche
罗氏 |
120 mg
Injection | 注射剂 |
ZL200980100709.6 | 1-3 | Sequence of active biological ingredients
生物制品活性成分的序列结构 |
2029-09-25 | |
| Obinutuzumab
奥妥珠单抗注射液 (GAZYVA®, 佳罗华®) CD20 antibody CD20单抗 |
Roche
罗氏 |
1000 mg
Injection | 注射剂 |
ZL200480039946.3 | 1-14, 24-26 | Sequence of active biological ingredients;
Medical use 生物制品活性成分的序列结构; 医药用途 |
2024-11-05 | |
| Denosumab
地舒单抗注射液 (XGEVA®, 安加维®) RANKL antibody 核因子-κB受体活化因子配体单抗 |
Amgen
安进 |
60 mg
Injection | 注射剂 |
ZL201310052370.5 | 1-25, 27-28 | Sequence of active biological ingredients;
Medical use 生物制品活性成分的序列结构; 医药用途 |
2022-06-24 | |
| Dupilumab
度普利尤单抗注射液 (DUPIXENT®, 達必妥®) High affinity IL-4 receptor antibody IL-4受体的高亲和性抗体 |
Regeneron
再生元 |
300 mg
Injection | 注射剂 |
ZL200980143007.6 | 1-5, 13, 16 | Sequence of active biological ingredients;
Medical use 生物制品活性成分的序列结构; 医药用途 |
2029-10-27 | |
| Regeneron
再生元 |
300 mg
Injection | 注射剂 |
ZL201410018529.6 | 1-8, 16 | Sequence of active biological ingredients;
Medical use 生物制品活性成分的序列结构; 医药用途 |
2029-10-27 | ||
| Ustekinumab
乌司奴单抗注射液 (STELARA®, 喜达诺®) IL-12 antibody 抗IL-12抗体 |
Janssen-Cilag
詹森 |
45, 90, 130 mg Injection | 注射剂 | ZL200810100025.3 | 1-6, 8-13 | Sequence of active biological ingredients
生物制品活性成分的序列结构 |
2021-08-06 | |
| Atezolizumab
阿替利珠单抗注射液 (TECENTRIQ®, 泰圣奇®) PD-L1 antibody 抗-PD-L1抗体 PD-L1 antibody 抗-PD-L1抗体 PDL1 antibody formulation 抗PDL1抗体配制剂 |
Roche
罗氏 |
1200 mg
Injection | 注射剂 |
ZL200980149532.9 | 1-8, 19, 40, 43, 53 | Sequence of active biological ingredients;
Medical use 生物制品活性成分的序列结构; 医药用途 |
2029-12-08 | |
| Roche
罗氏 |
1200 mg
Injection | 注射剂 |
ZL201410743500.4 | 1-13, 15, 34-40 | Sequence of active biological ingredients;
Medical use 生物制品活性成分的序列结构; 医药用途 |
2029-12-08 | ||
| Roche
罗氏 |
1200 mg
Injection | 注射剂 |
ZL201480064099.X | 36 | Medical use
医药用途 |
2034-09-26 | ||
| Guselkumab
古塞奇尤单抗注射液 (TREMFYA®, 特诺雅®) IL-23 antibody 抗IL-23抗体 |
Janssen-Cilag
詹森 |
100 mg
Injection | 注射剂 |
ZL200680053546.7 | 2, 4-8, 21-25 | Sequence of active biological ingredients
生物制品活性成分的序列结构 |
2026-12-27 | |
| Janssen-Cilag
詹森 |
100 mg
Injection | 注射剂 |
ZL201210297501.1 | 1-5 | Sequence of active biological ingredients
生物制品活性成分的序列结构 |
2026-12-27 | ||
| Alirocumab
阿利西尤单抗注射液 (PRALUENT®, 波立达®) High affinity PCSK9 antibody 抗PCSK9的高亲和力抗体 Methods of reducing lipoprotein with PCSK9 inhibitors 用PCSK9抑制剂降低脂蛋白的方法 |
Regeneron
再生元 |
75, 150 mg Injection | 注射剂 | ZL200980150206.X | 1-2, 8-9 | Sequence of active biological ingredients;
Medical use 生物制品活性成分的序列结构; 医药用途 |
2029-12-15 | |
| Regeneron
再生元 |
75, 150 mg Injection | 注射剂 | ZL201280044795.5 | 1-8, 11-12, 15-23 | Medical use
医药用途 |
2032-09-12 | ||
| Durvalumab
度伐利尤单抗注射液 (IMFINZI®, 英飞凡®) B7-H1 binding agent 针对B7-H1的靶向结合剂 |
AstraZeneca
阿斯利康 |
120, 500 mg Injection | 注射剂 | ZL201080053042.1 | 1-4, 6-8, 10-12 | Sequence of active biological ingredients
生物制品活性成分的序列结构 |
2030-11-24 | |
| Ixekizumab
依奇珠单抗注射液 (TALTZ®, 拓咨®) IL-17 antibody 抗 IL-17 抗体 |
Eli Lilly
礼来
|
80 mg
Injection | 注射剂
|
ZL200680046605.8 | 1-7 | Sequence of active biological ingredients;
Medical use 生物制品活性成分的序列结构; 医药用途 |
2026-12-05 | |
| ZL201380012452.5 | 1-10 | Medical use
医药用途 |
2033-03-01 | ||||
| Daratumumab
达雷妥尤单抗注射液 (DARZALEX®, 兆珂®) CD38 antibody CD38抗体 |
Janssen-Cilag
詹森 |
100, 400 mg Injection | 注射剂 | ZL200680017915.7 | 1-4, 6, 8-10, 13, 29-30, 33-36, 40 | Sequence of active biological ingredients;
Medical use 生物制品活性成分的序列结构; 医药用途 |
2026-03-22 | |
| 100, 400 mg Injection | 注射剂 | ZL201710164800.0 | 19-20, 22, 24-27, 29 | Medical use
医药用途 |
2026-03-22 | |||
| Recombinant Zoster Vaccine (CHO cell)
重组带状疱疹疫苗(CHO细胞) (SHINGRIX®, 欣安立适®) Vaccine 疫苗 |
GSK
葛兰素史克
|
IgE 50 μg
Injection | 注射剂 |
ZL201210552767.6 | 1-4 | Medical use
医药用途 |
2026-03-01 | |
| Denosumab
地舒单抗注射液 OPGL antibody 抗OPGL抗体 |
Amgen
安进 |
120 mg
Injection | 注射剂 |
ZL201310052370.5 | 1-25, 27-32 | Sequence of active biological ingredients;
Medical use 生物制品活性成分的序列结构; 医药用途 |
2022-06-24 | |
| Secukinumab
司库奇尤单抗注射液 (COSENTYX®, 可善挺®) Interleukin (IL)-17A antibody IL-17A抗体 |
Novartis
诺华 |
150 mg
Injection | 注射剂 |
ZL200580026569.4 | 1-5 | Sequence of active biological ingredients
生物制品活性成分的序列结构 |
2025-08-04 | |
| Dulaglutide
度拉糖肽注射液 (TRULICITY®, 度易达®) GLP-1 analogue fusion protein GLP-1 类似物融合蛋白质 |
Eli Lilly
礼来
|
0.75, 1.5 mg Injection | 注射剂 | ZL200480015953.X | 1-4, 6-7, 9, 10 | Sequence of active biological ingredients;
Medical use 生物制品活性成分的序列结构; 医药用途 |
2024-06-10 | |
| 0.75, 1.5 mg Injection | 注射剂 | ZL201010508567.1 | 1, 2 | Sequence of active biological ingredients
生物制品活性成分的序列结构 |
2024-06-10 | |||
| 0.75, 1.5 mg Injection | 注射剂 | ZL200580035597.2 | 1-4, 8 | Medical use
医药用途 |
2025-12-15 | |||
| Pertuzumab帕妥珠单抗注射液
(PERJETA®, 帕捷特®) HER2 antibody 针对HER2的抗体 |
健泰科生物
|
420 mg
Injection | 注射剂
|
ZL201210006776.5 | 1-6, 8-11, 13, 15, 19-27 | Medical use
医药用途 |
2025-06-15 | |
| ZL200680013738.5 | 1-2, 5-14 | Medical use
医药用途 |
2026-02-21 | ||||
| ZL200980111007.8 | 9, 10 | Medical use
医药用途 |
2029-01-28 | ||||
| ZL200580031905.4 | 12, 13 | Medical use
医药用途 |
2025-07-15 | ||||
| Emicizumab
艾美赛珠单抗注射液 (HEMLIBRA®, 舒友立乐®) Multispecific antigen-binding molecule (coagulation factor VIII replaceable) 代替凝血因子VIII 的多特异性抗原结合分子 |
Chugai
中外制药
|
30, 60, 105, 150 mg Injection | 注射剂
|
ZL201180065133.1 | 1, 13 | Sequence of active biological ingredients;
Medical use 生物制品活性成分的序列结构; 医药用途 |
2031-11-17 | |
| ZL201610299812.X | 1, 9-12 | Sequence of active biological ingredients;
Medical use 生物制品活性成分的序列结构; 医药用途 |
2031-11-17 | ||||
| Evolocumab
依洛尤单抗注射液 (REPATHA®, 瑞百安®) Proprotein convertase subtilisin/kexin type 9 (PCSK9) antibody针对人前蛋白转化酶枯草溶菌素kexin 9型的抗体 |
Amgen
安进
|
140 mg
Injection | 注射剂
|
ZL201380035382.5 | 17-20 | Medical use
医药用途 |
2033-05-02 | |
| ZL200880113475.4 | 1-7, 9-14, 16-17, 25-29 | Sequence of active biological ingredients;
Medical use 生物制品活性成分的序列结构; 医药用途 |
2028-08-21 | ||||
| ZL201280034417.9 | 2-23, 27, 33-35, 37, 39, 40, 42, 43, 47-52, 54-58, 60 | Medical use
医药用途 |
2032-05-09 | ||||
| Pembrolizumab
帕博利珠单抗注射液 (KEYTRUDA®, 可瑞达®) PD-1 antibody 针对PD-1的抗体 |
Merck
默沙东 |
100 mg
Injection | 注射剂 |
ZL200880103544.3 | 1-4, 13 | Sequence of active biological ingredients
生物制品活性成分的序列结构 |
2028-06-13 | |
| Nivolumab
纳武利尤单抗注射液 (OPDIVO®, 欧狄沃®) PD-1 antibody 针对PD-1的抗体 |
Ono Pharmaceutical
小野薬品
|
40, 100 mg Injection | 注射剂 | ZL200680023860.0 | 1-3, 11-13, 15-16 | Sequence of active biological ingredients;
Medical use 生物制品活性成分的序列结构; 医药用途 |
2026-05-02 | |
| ZL201210554886.5 | 1-15, 28-30 | Sequence of active biological ingredients;
Medical use 生物制品活性成分的序列结构; 医药用途 |
2026-05-02 | ||||
| Idarucizumab
依达赛珠单抗注射液 (PRAXBIND®, 泰毕安®) Anticoagulant antibody 抗凝血剂抗体 |
Boehringer Ingelheim
宝灵家殷格翰 |
2.5 g
Injection | 注射剂 |
ZL201180006616.4 | 1, 2-3, 9 | Sequence of active biological ingredients;
Medical use 生物制品活性成分的序列结构; 医药用途 |
2031-01-20 | |
| Recombinant Human Papillomavirus 9-Valent (Types 6, 11, 16, 18, 31, 33, 45, 52, 58) Vaccine
九价人乳头瘤病毒疫苗（酿酒酵母） (GARDASIL 9®, 佳达修9®) 9-valent human papillomavirus (9vHPV) vaccine 九价宫颈癌（HPV）疫苗 |
Merck
默沙东
|
0.5 mL
Injection | 注射剂
|
ZL200480007725.8 | 1, 12 | Sequence of active biological ingredients
生物制品活性成分的序列结构 |
2024-03-19 | |
| ZL200480028106.7 | 1 | Sequence of active biological ingredients
生物制品活性成分的序列结构 |
2024-09-24 | ||||
| ZL03806347.6 | 21, 23 | Medical use
医药用途 |
2023-03-17 | ||||
| ZL200580019515.5 | 19, 20 | Medical use
医药用途 |
2025-06-14 | ||||
| Tocilizumab
托珠单抗注射液 (ACTEMRA®, 雅美罗®) Interleukin-6 receptor (IL-6R) antibody 针对白介素6受体的抗体 |
Chugai
中外制药
|
80, 200,
400 mg Injection | 注射剂
|
ZL02807784.9 | 1-4, 6-7, 9-21, 23-24, 26-27, 29 | Medical use
医药用途 |
2022-04-02 | |
| ZL200480011401.1 | 10-18 | Medical use
医药用途 |
2024-04-28 | ||||
| ZL201511004468.9 | 7-12 | Medical use
医药用途 |
2024-04-28 | ||||
| Golimumab
戈利木单抗注射液 (SIMPONI®, 欣普尼®) TNF-α antibody 针对TNF-α的抗体 |
Janssen Biologics
詹森生物
|
50 mg
Injection | 注射剂 |
ZL01816960.0 | 1-3, 10-12 | Sequence of active biological ingredients
生物制品活性成分的序列结构 |
2021-08-06 | |
| 50 mg
Injection | 注射剂 |
ZL201010156291.5 | 1-8 | Medical use
医药用途 |
2021-08-06 | |||
| Recombinant Human Papillomavirus Quadrivalent (Types 6, 11, 16, 18) Vaccine
四价人乳头瘤病毒疫苗（酿酒酵母） (GARDASIL®, 佳达修®) 4-valent human papillomavirus (4vHPV) vaccine 四价宫颈癌（HPV）疫苗
|
Merck
默沙
|
0.5 mL
Injection | 注射剂
|
ZL03806347.6 | 21, 23 | Medical use
医药用途 |
2023-03-17 | |
| ZL200580019515.5 | 19, 20 | Medical use
医药用途 |
2025-06-14 | ||||
| 13-Valent Pneumococcal Polysaccharide Conjugate Vaccine
13价肺炎球菌多糖结合疫苗 (PREVENAR 13®, 沛儿®) Multivalent pneumococcal polysaccharide conjugate composition 多价肺炎球菌多糖-蛋白质缀合物组合物 |
Wyeth
惠氏 |
0.5 mL
Injection | 注射剂 |
ZL200680017776.8 | 6-7 | Medical use
医药用途 |
2026-03-30 | |
| Influenza Vaccine (Split Virion)
流感病毒裂解疫苗 Method for virus splitting and inactivation by using influenza vaccine (split virion) 一种人用流感病毒裂解疫苗的病毒裂解灭活方法 |
Changchun
长春生物 |
0.5 mL
Injection | 注射剂 |
ZL201210129270.3 | 1 | Medical use
医药用途 |
2032-04-27 | |
| Cenegermin
塞奈吉明滴眼液 (OXERVATE™) Recombinant human nerve growth factor (rhNGF) 重组人神经生长因子 |
Dompé farmaceutici S.p.A. | 1 mL:20 μg
Eye drop | 滴眼液 |
ZL201280062855.6 | 1-3, 4-27 | Sequence of active biological ingredients;
Medical use 生物制品活性成分的序列结构; 医药用途 |
2032-12-18 |
1 China has implemented a patent linkage system in the fourth amendments to its patent law, which became effective June 1, 2021 (Article 76 of the Patent Law of the People’s Republic of China (2020)). A patent registration platform has been set up for the Marketing Authorization Holder (MAH) to register certain drug product-related patent information. For biologics, patents may be registered include those directed to the active pharmaceutical ingredient (API) sequence/structure information and medical use.
2 Excluding any patent term adjustment or patent term extension. The fourth amendment to the Chinese patent law introduces the patent term adjustment (PTA) and patent term extension (PTE).